查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1722876

2025 年至 2033 年抗肥胖药物市场规模、份额、趋势及预测（依药物类别、药物类型、配销通路及地区划分）

Anti-Obesity Drugs Market Size, Share, Trends and Forecast by Drug Class, Drug Type, Distribution Channel, and Region, 2025-2033
出版日期: | 出版商: IMARC | 英文 141 Pages | 商品交期: 2-3个工作天内

价格

2024 年全球抗肥胖药物市场规模价值 25 亿美元。展望未来， IMARC Group估计到 2033 年市场规模将达到 59 亿美元，2025 年至 2033 年的复合年增长率为 9.89%。北美目前占据市场主导地位，2024 年的市占率将超过 36.7%。由于肥胖率上升、健康意识增强、对体重管理解决方案的需求、药物开发的进步、政府倡议、研发投资、联合疗法以及处方药和非处方药的可用性，抗肥胖药物的市场份额正在增加。

减肥药的目的是减少或控制体重，一般只在病态肥胖的情况下才开处方。它们有助于减少食慾并控制强迫性饮食，特别是对甜食、油腻、咸味和高热量食品的渴望。它们还可以提供独立的健康益处，例如控制血压、有害脂质水平、腰围、血糖水平和非酒精性脂肪肝病（NAFLD），并最大限度地降低主要心血管疾病（CVD）和糖尿病肾病变进展的风险。

抗肥胖药物市场趋势：

抗肥胖药物的最新进展使得个人有可能实现临床上显着的减肥效果。这与久坐不动的生活方式导致的肥胖症的普遍流行相结合，是创造积极市场前景的关键因素之一。此外，肥胖会增加罹患第 2 型糖尿病 (T2D)、心血管疾病 (CVD) 以及食道癌、结肠癌、直肠癌、肝癌、胆囊癌、胰臟癌和肾癌的风险。它还会导致许多心理、神经、肺、胃肠道、肾臟、肌肉骨骼和内分泌疾病。除此之外，睡眠不足、昼夜节律不同步、慢性压力以及抗癫痫和精神药物的使用增加都可能进一步导致体重增加。再加上有助于调节食慾和食物渴望的抗肥胖药物（AOM）的批准数量不断增加，推动了市场的成长。除此之外，减重有助于改善个人的生活品质、活动能力、日常功能和心理健康。预计这一趋势，加上人们健康意识的增强、製药业的蓬勃发展以及对与体重超重密切相关的疾病管理的日益关注，将刺激市场的成长。

本报告回答的关键问题

  • 减肥药市场有多大？减肥药市场未来前景如何？
  • 推动抗肥胖药物市场发展的关键因素有哪些？
  • 哪个地区占减重药物最大的市场份额？
  • 全球抗肥胖药物市场领先的公司有哪些？

目录

第一章：前言

第二章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 次要来源
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章：执行摘要

第四章：简介

  • 概述
  • 主要行业趋势

第五章：全球抗肥胖药物市场

  • 市场概览
  • 市场表现
  • COVID-19的影响
  • 市场预测

第六章：市场区隔：依药品类别

  • 週边作用药物
  • 中枢作用药物

第七章：市场区隔：依药物类型

  • 处方药
  • 非处方药

第八章：市场区隔：按配销通路

  • 医院药房
  • 零售药局
  • 网路药局

第九章：市场细分：依地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场区隔：依国家

第十章：SWOT分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 11 章：价值链分析

第 12 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第十三章：价格分析

第 14 章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Boehringer Ingelheim International GmbH
    • Currax Pharmaceuticals LLC
    • Gelesis
    • GlaxoSmithKline plc
    • Merck & Co. Inc.
    • Norgine BV
    • Novo Nordisk A/S
    • Pfizer Inc.
    • Rhythm Pharmaceuticals Inc.
    • SHIONOGI & Co. Ltd.
    • Takeda Pharmaceutical Company Limited
    • Vivus LLC
Product Code: SR112025A5544

The global anti-obesity drugs market size was valued at USD 2.5 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 5.9 Billion by 2033, exhibiting a CAGR of 9.89% from 2025-2033. North America currently dominates the market, holding a market share of over 36.7% in 2024. The anti-obesity drugs market share is increasing due to the rising obesity rates, health awareness, demand for weight management solutions, drug development advancements, government initiatives, R&D investments, combination therapies, and availability of prescription and over-the-counter drugs.

Anti-obesity drugs are intended to reduce or control weight and generally medically prescribed only in cases of morbid obesity. They help reduce cravings and control compulsive eating, especially for sweets and fatty, salty, and high-calorie food products. They can also provide independent health benefits, such as controlling blood pressure, harmful lipid levels, waist circumference, sugar levels and nonalcoholic fatty liver disease (NAFLD) and minimize the risk of major cardiovascular diseases (CVDs) and progression of diabetic kidney disease.

Anti-Obesity Drugs Market Trends:

Recent advances in anti-obesity drugs have enabled the potential of attaining clinically significant weight loss among individuals. This, in confluence with the widespread prevalence of obesity on account of sedentary lifestyles, represents one of the key factors creating a positive outlook for the market. In addition, obesity increases the risk of developing type 2 diabetes (T2D), cardiovascular diseases (CVD), and cancer of the esophagus, colon and rectum, liver, gallbladder, pancreas, and kidney. It can also result in numerous psychological, neurological, pulmonary, gastrointestinal, renal, musculoskeletal, and endocrine diseases. Besides this, sleep deprivation, circadian desynchronization, chronic stress, and the rising use of anti-epileptic and psychotropic drugs may further induce weight gain. This, coupled with the increasing number of approvals of anti-obesity medications (AOMs) that help regulate appetite and food cravings, is fueling the growth of the market. Apart from this, weight loss aids in improving the quality of life, mobility, daily function, and psychological well-being of individuals. This, along with the increasing health consciousness, thriving pharmaceutical industry, and the rising focus on the management of diseases closely integrated with excess body weight, is anticipated to stimulate the growth of the market.

Key Market Segmentation:

Breakup by Drug Class:

  • Peripherally Acting Drugs
  • Centrally Acting Drugs

Breakup by Drug Type:

  • Prescription Drugs
  • OTC Drugs

Breakup by Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Boehringer Ingelheim International GmbH, Currax Pharmaceuticals LLC, Gelesis, GlaxoSmithKline plc, Merck & Co. Inc., Norgine B.V., Novo Nordisk A/S, Pfizer Inc., Rhythm Pharmaceuticals Inc., SHIONOGI & Co. Ltd., Takeda Pharmaceutical Company Limited and Vivus LLC.

Key Questions Answered in This Report

  • 1.How big is the anti-obesity drugs market?
  • 2.What is the future outlook of anti-obesity drugs market?
  • 3.What are the key factors driving the anti-obesity drugs market?
  • 4.Which region accounts for the largest anti-obesity drugs market share?
  • 5.Which are the leading companies in the global anti-obesity drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Anti-Obesity Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 Peripherally Acting Drugs
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Centrally Acting Drugs
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Drug Type

  • 7.1 Prescription Drugs
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 OTC Drugs
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospital Pharmacy
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Retail Pharmacy
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Online Pharmacy
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Boehringer Ingelheim International GmbH
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
    • 14.3.2 Currax Pharmaceuticals LLC
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
    • 14.3.3 Gelesis
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
    • 14.3.4 GlaxoSmithKline plc
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Merck & Co. Inc.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Norgine B.V.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
    • 14.3.7 Novo Nordisk A/S
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Pfizer Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
    • 14.3.9 Rhythm Pharmaceuticals Inc.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
    • 14.3.10 SHIONOGI & Co. Ltd.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Takeda Pharmaceutical Company Limited
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 Vivus LLC
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio

List of Figures

  • Figure 1: Global: Anti-Obesity Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Anti-Obesity Drugs Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Anti-Obesity Drugs Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Anti-Obesity Drugs Market: Breakup by Drug Class (in %), 2024
  • Figure 5: Global: Anti-Obesity Drugs Market: Breakup by Drug Type (in %), 2024
  • Figure 6: Global: Anti-Obesity Drugs Market: Breakup by Distribution Channel (in %), 2024
  • Figure 7: Global: Anti-Obesity Drugs Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Anti-Obesity Drugs (Peripherally Acting Drugs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Anti-Obesity Drugs (Peripherally Acting Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Anti-Obesity Drugs (Centrally Acting Drugs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Anti-Obesity Drugs (Centrally Acting Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Anti-Obesity Drugs (Prescription Drugs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Anti-Obesity Drugs (Prescription Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Anti-Obesity Drugs (OTC Drugs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Anti-Obesity Drugs (OTC Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Anti-Obesity Drugs (Hospital Pharmacy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Anti-Obesity Drugs (Hospital Pharmacy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Anti-Obesity Drugs (Retail Pharmacy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Anti-Obesity Drugs (Retail Pharmacy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Anti-Obesity Drugs (Online Pharmacy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Anti-Obesity Drugs (Online Pharmacy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: North America: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: North America: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: United States: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: United States: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Canada: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Canada: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: Asia-Pacific: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: Asia-Pacific: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: China: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: China: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: Japan: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: Japan: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: India: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: India: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: South Korea: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: South Korea: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: Australia: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: Australia: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: Indonesia: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: Indonesia: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: Others: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: Others: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: Europe: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: Europe: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: Germany: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: Germany: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: France: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: France: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: United Kingdom: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: United Kingdom: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: Italy: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: Italy: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: Spain: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: Spain: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: Russia: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: Russia: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: Others: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: Others: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: Latin America: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: Latin America: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: Brazil: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: Brazil: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: Mexico: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: Mexico: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Others: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: Others: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Middle East and Africa: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Middle East and Africa: Anti-Obesity Drugs Market: Breakup by Country (in %), 2024
  • Figure 70: Middle East and Africa: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: Global: Anti-Obesity Drugs Industry: SWOT Analysis
  • Figure 72: Global: Anti-Obesity Drugs Industry: Value Chain Analysis
  • Figure 73: Global: Anti-Obesity Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Anti-Obesity Drugs Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Anti-Obesity Drugs Market Forecast: Breakup by Drug Class (in Million USD), 2025-2033
  • Table 3: Global: Anti-Obesity Drugs Market Forecast: Breakup by Drug Type (in Million USD), 2025-2033
  • Table 4: Global: Anti-Obesity Drugs Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
  • Table 5: Global: Anti-Obesity Drugs Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 6: Global: Anti-Obesity Drugs Market: Competitive Structure
  • Table 7: Global: Anti-Obesity Drugs Market: Key Players